AzTrials
AzTrials

SepsisNCT07843277

Implementation of a Sepsis Chart and Its Effects on Mortality Rate in Indonesian Primary Referral Hospitals

An observational study of Sepsis and Antimicrobial Resistance (AMR), run by Dr Cipto Mangunkusumo General Hospital at 2 sites in Indonesia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to evaluate the effectiveness of implementing Koran Sepsis, or sepsis chart, a paper-based order set designed to guide the implementation of the One-hour Sepsis Bundle, in improving adherence to early sepsis management and reducing 7-day mortality among adult patients with… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Sepsis, Antimicrobial Resistance (AMR)
What is being tested?
Sepsis chart (koran sepsis)
How many people
304 participants
Where
2 sitesIndonesia
Study dates
1 Sep 2026to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients above ≥18 years diagnosed with sepsis in the emergency department in Cipto Mangunkusumo and Fatmawati General Hospital.

Who may be able to join

  • Adult patients aged ≥18 years.
  • Patients diagnosed with sepsis according to the Sepsis-3 definition, using the lactate-modified qSOFA score as a reference.
  • Patients presenting to the Emergency Department.
  • Patients who are subsequently admitted to one of the participating hospitals: Cipto Mangunkusumo and Fatmawati General Hospital.

Who cannot join

  • Incomplete clinical or outcome data required for the study analysis.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Sharifah Shakinah, MD contact

+628129670607

sharifah.shakinah@gmail.com

Indonesia2 sites, 2 recruiting
  • Dr Cipto Mangunkusumo General Hospital

    Jakarta Pusat, DKI Jakarta, 10430

    Sharifah Shakinah, MD, +628129670607, sharifah.shakinah@gmail.com

    Sharifah Shakinah, MD

    Recruiting
  • Fatmawati General Hospital

    Jakarta Pusat, DKI Jakarta, 10430

    Krishna A Wibisana, MD, +628561256154, k.wibisana@gmail.com

    Not yet recruiting

Other trials in Indonesia

About this study

The goal of this observational study is to evaluate the effectiveness of implementing Koran Sepsis, or sepsis chart, a paper-based order set designed to guide the implementation of the One-hour Sepsis Bundle, in improving adherence to early sepsis management and reducing 7-day mortality among adult patients with sepsis presenting to the Emergency Department. The main questions it aims to answer are:

  1. Does implementation of a sepsis chart improve adherence to the One-hour Sepsis Bundle among adult patients with sepsis?
  2. Does implementation of a sepsis chart reduce 7-day mortality among adult patients with sepsis?
Read more

Researchers will compare the period before and after implementation of Koran Sepsis to determine whether its implementation improves adherence to the One-hour Sepsis Bundle and reduces 7-day mortality.

Participants will:

  • Receive standard clinical care for sepsis, with management documented during the first hour after sepsis is suspected or diagnosed.
  • Receive care guided by sepsis chart after its implementation at the participating hospital.
  • Have clinical data collected from their medical records, including adherence to the One-hour Sepsis Bundle and time to administration of broad-spectrum antibiotics.
  • Be followed for seven days to determine their mortality outcome.

The study will include adult patients aged ≥18 years diagnosed with sepsis according to the Sepsis-3 definition who present to the Emergency Department and are admitted to one of two participating hospitals: Cipto Mangunkusumo and Fatmawati General Hospital.

Read the detailed description

Background

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. If not recognized and treated promptly, sepsis may progress to septic shock, resulting in multiple organ failure and death. Sepsis is a serious complication of infectious diseases and remains one of the leading causes of death worldwide, particularly in low- and middle-income countries.

Globally, an estimated 48.9 million cases of sepsis occurred in 2017, with approximately 11 million sepsis-related deaths, accounting for 19.7% of all global deaths. Data from 16 Asian countries reported an intensive care unit mortality rate of 44.5% among patients with sepsis. At Dr. Cipto Mangunkusumo National Referral Hospital (RSCM), a 2017 study reported that 64% of adult patients with infection had sepsis, defined as a Sequential Organ Failure Assessment (SOFA) score >2. Another study conducted between 2016 and 2022 reported a mortality rate of 69% among patients with sepsis at RSCM, with a higher risk of mortality among patients with metabolic comorbidities. Data from the Community Services Coordinator of the Department of Internal Medicine at RSCM also showed that 10.3% of internal medicine inpatients were diagnosed with sepsis.

The One-hour Sepsis Bundle is a set of interventions recommended to be initiated within the first hour of suspected sepsis. These interventions include measurement of serum lactate, collection of blood cultures, administration of broad-spectrum antibiotics, fluid resuscitation, and hemodynamic management, with the aim of improving tissue perfusion and achieving early infection control.

Although several studies have demonstrated the effectiveness of the One-hour Sepsis Bundle in reducing mortality, its implementation at RSCM has not been systematically evaluated. Currently, there is no specific sepsis scoring system integrated into the Hospital Information System (HIS) or clinical pathway for patients with sepsis. In addition, a review by the Medical Committee indicated that the One-hour Sepsis Bundle had not been implemented in the majority of sepsis cases presenting to the Emergency Department (ED).

Previous studies have demonstrated that the use of sepsis forms and implementation of sepsis codes may reduce mortality and length of hospital stay. One approach to improving implementation is Koran Sepsis, a paper-based order set designed to guide healthcare professionals in delivering the One-hour Sepsis Bundle. This study aims to evaluate the effectiveness of Koran Sepsis implementation on short-term mortality, defined as 7-day mortality, among patients with sepsis at during the period of September 2026 - 2027

Objectives

The primary objective of this study is to evaluate the effectiveness of Koran Sepsis implementation in improving adherence to the One-hour Sepsis Bundle and reducing 7-day mortality among patients with sepsis.

Specifically, this study aims to determine the proportion of patients receiving initial sepsis management according to the One-hour Sepsis Bundle prior to Koran Sepsis implementation and to determine the proportion of healthcare professionals adhering to the One-hour Sepsis Bundle following its implementation. The study will also compare adherence to the One-hour Sepsis Bundle before and after Koran Sepsis implementation and assess differences in 7-day mortality between the two periods.

In addition, this study aims to evaluate the association between individual components of the One-hour Sepsis Bundle, including serum lactate measurement, blood culture collection, administration of broad-spectrum antibiotics, fluid administration, and vasopressor administration, and 7-day mortality among patients with sepsis.

Study Design

This study is an observational study using a pragmatic stepped-wedge cluster design. The participating hospitals will transition sequentially from the standard-of-care period to the sepsis chart implementation period. The sequence of hospital implementation will be determined according to the order in which approval are obtained.

Sample Size Calculation

Based on the estimated number of participating hospitals, the number of steps in the stepped-wedge design, and the anticipated difference in proportions, the sample size was calculated using the formula proposed by Hemming et al., resulting in a total sample size of 304 patients from 2 hospitals.

Study Procedures and Data Collection

Patients meeting the operational definition of sepsis will be recruited consecutively during the study period. Their clinical management during the initial hour of sepsis care will be documented, including the implementation of each component of the One-hour Sepsis Bundle. Patients will subsequently be followed for seven days to determine their mortality outcome.

Data will be collected using a case report form completed by clinicians or trained research personnel based on information obtained from the patients' medical records. Information regarding sepsis management will be obtained from the electronic health record and Koran Sepsis documentation. All collected data will be processed anonymously to maintain patient confidentiality.

Study Variables and Parameters

The primary outcome of this study is 7-day mortality, defined as death occurring during hospitalization within seven days following admission.

Secondary outcomes include adherence to the One-hour Sepsis Bundle and the time to administration of broad-spectrum antibiotics. We will assess adherence to the One-hour Sepsis Bundle based on documentation of the relevant interventions in the electronic health record and Koran Sepsis. The components assessed will include serum lactate measurement, blood culture collection before antibiotic administration, administration of broad-spectrum antibiotics, administration of 30 mL/kg crystalloid fluid, and vasopressor administration when fluid resuscitation is inadequate or unsuccessful. The time to administration of broad-spectrum antibiotics will be defined as the time elapsed between sepsis diagnosis and antibiotic administration.

Patient-level characteristics that will be collected include age, sex, Charlson Comorbidity Index (CCI), lactate-modified qSOFA score, SOFA score, presence of septic shock, source of infection, and identified pathogen. Age will be categorized as 18-59 years and ≥60 years. The CCI will be calculated based on the patient's documented comorbidities and subsequently categorized as high or low according to the optimal cut-off derived from receiver operating characteristic (ROC) curve analysis. The lactate-modified qSOFA score will be determined based on clinical and laboratory parameters and categorized as high or low according to the cut-off derived from ROC curve analysis.

Hospital-level characteristics will also be collected to account for potential differences between participating centers. These variables will include the total number of inpatient admissions per month, total number of ED visits per month, number of inpatient beds, and the types of pathogens commonly identified at each hospital.

The primary exposure of interest is the implementation of Koran Sepsis. The primary clinical outcome is 7-day mortality. Adherence to the One-hour Sepsis Bundle will be evaluated as an implementation-related outcome and will also be assessed in relation to mortality. Potential confounding variables will include patient-level characteristics and hospital-level factors.

Data and Statistical Analysis

Data will undergo data entry, editing, coding, processing, and cleaning. Data quality will be assessed by identifying missing values, inconsistencies, and implausible variations before statistical analysis.

Statistical analyses will be performed using STATA version 15.1. Numerical variables will be presented as mean ± standard deviation (SD) for normally distributed data or as appropriate measures of central tendency and dispersion when the data are not normally distributed. Categorical variables will be presented as frequencies and percentages.

The primary and secondary outcomes will be analyzed using multilevel regression models to account for the clustering of observations within participating hospitals. The analysis will incorporate hospital-level random effects to account for between-hospital variability and intracluster correlation. The stepped-wedge design will also be taken into consideration in the analysis by accounting for the study period and intervention status.

This approach is intended to control for differences between participating hospitals and minimize potential bias arising from correlation among patients treated within the same hospital. Multivariable analysis will additionally be performed to adjust for relevant patient-level and hospital-level covariates. The association between individual components of the One-hour Sepsis Bundle and 7-day mortality will also be assessed. Relative risks will be calculated to compare mortality between patients who received management consistent with the One-hour Sepsis Bundle and those who did not.

Benefits

This study is expected to contribute to improving the quality of sepsis care at major hospitals in Indonesia by providing evidence regarding the implementation of the One-hour Sepsis Bundle in routine clinical practice.

The study may also identify specific aspects of early sepsis management that can be optimized to reduce mortality among patients with sepsis. Furthermore, the findings are expected to provide scientific evidence regarding the effectiveness of the One-hour Sepsis Bundle and Koran Sepsis, which may support the development of an effective and efficient system for the implementation of standardized sepsis management at participating hospitals.

Being tested
Sepsis chart (koran sepsis), Usual care
Keywords
sepsis, one-hour sepsis bundle
Medical subject headings
Sepsis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sepsis chart (koran sepsis)Other

    Implementation of the sepsis one-hour bundle using a paper-based chart containing instructions for the recommended bundle components.

  • Usual careOther

    Standard sepsis management according to existing hospital practice without implementation of the study-specific sepsis one-hour bundle order set.

Study groups in NCT07843277
Study groupRoleWhat they receive
Sepsis patientsAll patients included in the study, diagnosed with sepsis according to the sepsis-3 criteria
Receives: Other: Sepsis chart (koran sepsis); Other: Usual care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. All-cause mortality

    All death attributed to any reason during study follow-up

    Measured: 7 days

Secondary outcomes (5)
  1. Time to serum lactate measurement

    Time to serum lactate measurement to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Measured: Within 1 hour after sepsis diagnosis

  2. Time to Administration of Broad-Spectrum Antibiotics

    Time from sepsis diagnosis to administration of broad-spectrum antibiotics, based on documentation of patient management in the electronic health record (EHR) and sepsis record.

    Measured: Within 24 hours after study inclusion

  3. Time to blood culture collection

    Time to blood culture collection to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Measured: Within 1 hour after sepsis diagnosis

  4. Time to administration of 30 mL/kg crystalloid fluid

    Time to fluid administration to identify adherence to the sepsis one-hour bundle, as documented using the paper-based order set containing instructions for the sepsis one-hour bundle.

    Measured: Within 1 hour after sepsis diagnosis

  5. Vasopressor administration

    Identify whether any vasopressor is administered as needed.

    Measured: Within 24 hour after sepsis diagnosis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2026
  2. Study start1 Sep 2026
  3. Primary completion30 Sep 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
304 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07843277
Sponsor's protocol ID
26-04-0508
Status last verified
Sep 2026
First submitted
20 Sep 2026
Last updated
28 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Sepsis and Antimicrobial Resistance (AMR), run by Dr Cipto Mangunkusumo General Hospital at 2 sites in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sharifah Shakinah, MD (+628129670607, sharifah.shakinah@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

All-cause mortality (time frame: 7 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in